Welcome to our dedicated page for FDXTD news (Ticker: FDXTD), a resource for investors and traders seeking the latest updates and insights on FDXTD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FDXTD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FDXTD's position in the market.
FendX Technologies (OTCQB:FDXTD) has filed a provisional patent application with the USPTO for a novel medical catheter coating technology. The patent, titled "Lubricated Dilated Medical Catheters and Cannula and Uses Thereof," focuses on a specialized coating that provides dual benefits: enhanced patient comfort through reduced friction during insertion and reduced microbial growth on catheter surfaces.
The innovation, developed by Drs. Carolyn Myers, Tohid Didar, Martin Stark, and Leyla Soleymani, represents an advancement in FendX's portfolio of hygiene-related technologies, specifically targeting infection risk reduction in medical devices.